Cytiva Bio-Expo Live November 2026: Downstream Bioprocessing

As antibody-drug conjugates grow more diverse, manufacturing strategies must keep pace with increasingly complex molecules, payloads, and conjugation methods. Early coordination among discovery, cell line development, process development, and CMC teams can improve lead selection while reducing costly downstream challenges. Key considerations include accelerating stable cell line development, selecting workflows based on conjugation chemistry, and using automation to limit operator exposure to highly potent compounds. Facility design, containment, single-use assembly integrity, solvent compatibility, and extractables and leachables also play critical roles in protecting operators and patients. Flexible platforms can support established ADC processes while preparing facilities for multispecific antibodies, multiple payloads, and emerging formats.

Discover how a science-led manufacturing strategy can address current ADC requirements and adapt to the next generation of therapies.